Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Comparação da Necessidade de Anestesia para Ventilação com Tubo Endotraqueal Versus Máscara Laríngea Proseal Via Aérea

11 de novembro de 2026 atualizado por: Nitin Sethi, DNB, Sir Ganga Ram Hospital

Requisitos de anestesia para ventilação com tubo endotraqueal versus máscara laríngea ProSeal durante anestesia intravenosa total controlada por loop de feedback automatizado em pacientes submetidos a colecistectomia laparoscópica: um estudo controlado randomizado

Endotracheal tube (ETT) is the gold standard conduit for providing controlled ventilation during general anaesthesia (GA). however, the supra-glottic airway (SGA) devices in particular the laryngeal mask airway (LMA) and its variants have become a reliable alternative to ETT for carrying out controlled ventilation. Of the several variants of LMA available today, the proseal LMA (PLMA) is preferred for controlled ventilation. The various advantages of LMA includes, a lower incidence of postoperative sore throat and superior haemodynamic profile during surgery. However, one aspect of providing anaesthesia with LMA compared to ETT is the ability of LMA to maintain equivalent depth of anaesthesia with lower anaesthetic requirement, is quiet intriguing and evidence to this regard is very limited.

By measuring the anaesthesia requirement using a robust computerised delivery system such as the closed loop anaesthesia delivery system (CLADS) we can establish for sure the anaesthesia required for maintaining intraoperative mechanical ventilation with the use of these two (ETT and PLMA) airway management devices.

This randomised controlled study aims to calculate the anaesthesia requirement as determined by the total amount of propofol consumed for maintaining anaesthesia with ETT versus PLMA

Visão geral do estudo

Descrição detalhada

Endotracheal tube (ETT) is the gold standard conduit for providing controlled ventilation during general anesthesia (GA). However, since the introduction of classic laryngeal mask airway (LMA) in the 1980's and serial evolution of supra-glottic airway devices (SGA) thereafter, LMAs have become a reliable alternative to ETT for carrying out controlled ventilation. Interestingly, of the additional advantages that the LMA proffers, including, a lower incidence of postoperative sore throat (POST) and superior hemodyamic profile during surgery; its ability to maintain equivalent depth of anesthesia (in comparison to when ETT-GA) with lower anesthetic requirement, is intriguing.

A handful of studies have demonstrated that the end-tidal isoflurane concentration required for maintenance of GA is 0.2 -0.53% greater with use of ETT as compared to LMA. However, the evidence generated by these studies remains unsubstantiated because in them, anaesthetic gas concentration was titrated to patient's clinical profile like heart rate and blood pressure without the backing of specific protocol for maintaining depth-of-anaesthesia. Therefore, for credible evidence, assessment of quantitative anesthetic requirement for achieving and sustaining a steady anesthesia depth with either LMA or ETT warrants confirmation with the use of an objective depth-of-anesthesia monitor, such as, bispectral index (BIS).

Closed loop anaesthesia delivery system (CLADS) is an indigenously developed patented (502/DEL/2003) computer-controlled and BIS-guided automated anesthesia delivery system. CLADS, which runs on a control algorithm based on the relationship between diverse rates of propofol infusion and the processed EEG variable; delivers propofol infusion at a rate which is continuously adjusted by patient's state of depth of anesthesia as per BIS monitoring input. This automated system maintains anaesthesia depth with high accuracy and objectively determines propofol delivery quantitatively.

Of the several variants of SGA available today, the ProSeal laryngeal mask airway (PLMA) 9 is preferred for controlled ventilation for its unique design that serves dual function of a ventilation tube and an oropharyngeal drainage tube for excluding gastric contents from getting aspirated through the peri-laryngeal cuff seal.

Given that CLADS can help us to accurately quantify anaesthesia, we hypothesize that there is no difference in anesthesia requirement for GA maintained through an ETT or a PLMA. This randomized controlled study aims to compare: anaesthesia requirement as determined by total propofol consumption (primary objective); intraoperative hemodynamic profile and incidence of POST (secondary objectives) in patients undergoing laparoscopic surgery with controlled ventilation via ETT or PLMA.

Tipo de estudo

Intervencional

Inscrição (Real)

160

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • National Capital Territory of Delhi
      • New Delhi, National Capital Territory of Delhi, Índia, 110060
        • Sir Ganga Ram Hospital

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 65 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. ASA physical status I/II
  2. Undergoing elective laparoscopic cholecystectomy

Exclusion Criteria:

  1. Anticipated difficult airway
  2. Body mass index > 30-kg/m2
  3. Uncompensated cardiovascular disease (e.g. uncontrolled hypertension, atrio-ventricular block, sinus bradycardia, congenital heart disease, reduced LV compliance, diastolic dysfunction)
  4. Hepato-renal insufficiency
  5. Uncontrolled endocrinology disease (e.g. diabetes mellitus, hypothyroidism)
  6. Known allergy/hypersensitivity to the study drug (propofol)
  7. Drug dependence/substance abuse/psychiatric illness
  8. Requirement of postoperative ventilation
  9. Refusal to informed consent

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Outro
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: ETT Group

Anesthesia will be induced with fentanyl-citrate (3µg/kg) and propofol (dose determined by automated system based on continuous BIS feedback from the patients). Atracurium besylate 0.5-mg/kg will be given to facilitate placement of airway device. Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.

Intraoperative ventilation will be instituted through a polyvinyl chloride (PVC) ETT (Portex, Smiths Medical ASD, Inc, Minneapolis, USA). The size of the tube will be standardized for the male (7.5 mm ID) and the female (6.5 MM ID).

After induction of anaesthesia patient will be intubated with polyvinyl chloride (PVC) ETT for maintaining intraoperative ventilation. Anaesthesia will be maintained with propofol and the administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.

Comparador Ativo: PLMA Group

Anesthesia will be induced with fentanyl-citrate (3µg/kg) and propofol (dose determined by automated system based on continuous BIS feedback from the patients). Atracurium besylate 0.5-mg/kg will be given to facilitate placement of airway device. Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA. intraoperative ventilation will be maintained with PLMA (Telefex Medical, Westmeath Ireland) whose size would be selected based on body weight. In patients weighing 30-50 kg PLMA # 3.0, 50-70 kg PLMA # 4.0, and 50-100 kg PLMA # 5.0 will be inserted.

After induction of anaesthesia ProSeal Laryngeal Mask Airway (PLMA) will be inserted for maintaining intraoperative ventilation. Anaesthesia will be maintained with propofol and the administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change in Propofol usage in milligrams
Prazo: From beginning of anaesthesia (0-hours, baseline) till 4 hours intraoperatively

Comparison of quantitative difference in propofol requirement between the two groups

From beginning of anaesthesia (0-hours, baseline) till 4 hours intraoperatively

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Anaesthesia depth consistency using BIS scores
Prazo: From beginning of anaesthesia (0-hours, baseline) till 3 hours intraoperatively

Determined by the percentage of the total anaesthesia time in which the BIS scores remain within a score of 10% of the target BIS (i.e. BIS-50) in both the study arms.

From beginning of anaesthesia (0-hours, baseline) till 3 hours intraoperatively
Evaluation of propofol anaesthesia delivery system
Prazo: From beginning of anaesthesia (0-hours, baseline) till 3 hours intraoperatively

Determined by using Varvel criteria parameters; median performance error (MDP), median absolute performance error (MDAPE), wobble and global score in both the study arms

From beginning of anaesthesia (0-hours, baseline) till 3 hours intraoperatively
Change in Intra-operative heart Rate (beats per minute)
Prazo: From beginning of anaesthesia (0-hours, baseline) till 3 hours intraoperatively

Comparison of intra-operative heart rate between both the arms will be done

From beginning of anaesthesia (0-hours, baseline) till 3 hours intraoperatively
Change in Intra-operative systolic , diastolic, and mean (mmHg)
Prazo: From beginning of anaesthesia (0-hours, baseline) till 10 hours intraoperatively

Comparison of intra-operative blood pressure- systolic, diastolic, and mean between both the arms will be done

From beginning of anaesthesia (0-hours, baseline) till 10 hours intraoperatively
Early Recovery from anesthesia
Prazo: From end of anaesthesia till 20-minutes postoperatively

Time taken by the patient to open his/her eyes after discontinuation of anaesthesia will be noted

From end of anaesthesia till 20-minutes postoperatively
Post operative sedation
Prazo: From the end of anaesthesia till 24-hours, postoperatively

Will be assessed using Modified Observer's assessment of alertness/sedation scale (MOAA/S)

From the end of anaesthesia till 24-hours, postoperatively
Incidence of postoperative sore throat
Prazo: From the end of anaesthesia till 24-hours, postoperatively

Comparison of post operative sore throat occurrence between the two groups

From the end of anaesthesia till 24-hours, postoperatively

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Nitin Sethi, DNB, Sir Ganga Ram Hospital
  • Diretor de estudo: Amitabh Dutta, MD, Sir Ganga Ram Hospital
  • Cadeira de estudo: Jayashree Sood, MD, FFRCA, Sir Ganga Ram Hospital

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

4 de março de 2019

Conclusão Primária (Real)

3 de outubro de 2026

Conclusão do estudo (Real)

3 de outubro de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

19 de janeiro de 2019

Enviado pela primeira vez que atendeu aos critérios de CQ

19 de janeiro de 2019

Primeira postagem (Real)

23 de janeiro de 2019

Atualizações de registro de estudo

Última Atualização Postada (Real)

12 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

11 de novembro de 2026

Última verificação

1 de abril de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • EC/01/19/1464

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever